Cardio-vascular
Refine Search
Pharmaceutical
New Zealand's Pharmaceutical Managment Agency PHARMAC has agreed to fund four new medicines for which there are currently limited medicine options. 20 October 2014
Pharmaceutical
Blockbuster erectile dysfunction drug Viagra (sildenafil) could be used as a safe treatment for heart disease, finds new research published in the open access journal BMC Medicine. The study reveals that long-term daily treatment of Viagra can provide protection for the heart at different stages of heart disease, with few side effects. 20 October 2014
Biotechnology
USA-based Amgen has filed a law suit in the US District Court of Delaware against French pharma major Sanofi and US biotech Regeneron Pharmaceuticals for patent infringement of US Patent Numbers 8,563,698, 8,829,165, and 8,859,741. 19 October 2014
Pharmaceutical
The UK subsidiary of German family-owned pharma major Boehringer Ingelheim announced today that, following separate full reviews, the Scottish Medicines Consortium (SMC) has approved two of its medicines for use by NHS Scotland. 14 October 2014
Biotechnology
MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca, and Japanese drug discovery-based pharma company Shionogi have entered into a global license agreement under which MedImmune will in-license Shionogi’s preclinical biologic program for the potential treatment of acute coronary syndrome. 9 October 2014
Biotechnology
Belgium biotech firm Cardio3 BioSciences says it has signed a preferred access agreement with the USA’s Mayo Clinic. 8 October 2014
Pharmaceutical
USA-based Perosphere has entered into a third clinical trial collaboration agreement with Japanese pharma major Daiichi Sankyo to study PER977, Perosphere's investigational anticoagulant reversal agent, in Phase III registration studies with edoxaban, Daiichi Sankyo’s investigational oral, once-daily, direct factor Xa-inhibitor. 7 October 2014
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca today confirmed that the American Heart Association (AHA) and American College of Cardiology (ACC) have updated the guideline for the management of patients with non–ST-elevation acute coronary syndromes (NSTE-ACS). 6 October 2014
Biotechnology
The key message from European Partnering and Investment Conference in biotech, held yesterday in London, was that it is essential to prove the commercial viability of propositions, not simply that they are a good idea, from CNS drugs to Ebola testing. 3 October 2014
Pharmaceutical
Portola Pharmaceuticals says that its first Phase III study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and US Food and Drug Administration-designated breakthrough therapy, met its primary and secondary endpoints with high statistical significance. 1 October 2014
Pharmaceutical
The Japanese Ministry of Health, Labor and Welfare has granted approval for domestic pharma major Daiichi Sankyo’s Lixiana (edoxaban tosylate) for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism]. 29 September 2014
Pharmaceutical
Japan’s largest drugmaker Takeda Pharmaceutical has made a strategic investment in USA-based BioMotiv, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development. 25 September 2014
Pharmaceutical
Patients who were treated with a statin in hospital after suffering from a hemorrhagic stroke were significantly more likely to survive than those who were not, according to a study published in JAMA Neurology. 24 September 2014
Pharmaceutical
Privately-held Swiss pharma company Cardiorentis AG has entered into a €45 million ($58.3 million) financing agreement with US-based healthcare investment firm HealthCare Royalty Partners. 17 September 2014
Pharmaceutical
French pharma major Sanofi has signed a global collaboration with privately-held US firm MyoKardia to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases. 17 September 2014
Biotechnology
Merck Serono, the biotech unit of Germany’s Merck KGaA, has entered a strategic partnership with Indian pharma major Lupin as part of the drugmaker’s expansion in to emerging markets. 17 September 2014
Pharmaceutical
Shares of US biotech firm Amarin Corp tanked 23.7% to $1.38 on Friday in heavy trading, when the company revealed that the US Food and Drug Administration’s Office of New Drugs had denied its appeal of the FDA's rescission of the ANCHOR clinical trial Special Protocol Assessment agreement relating to Vascepa (icosapent ethyl). 14 September 2014
Generics
US generic drugs major Mylan has entered into an agreement to acquire the US commercialization, marketing and intellectual property rights relating to Arixtra (fondaparinux sodium) Injection and the authorized generic (AG) of Arixtra from South Africa’s Aspen. 10 September 2014
Pharmaceutical
Ireland-based generic drug major Actavis yesterday confirmed that the US Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee has voted by six to four to not recommend approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. 10 September 2014
Pharmaceutical
Hong Kong-based Luye Pharma has entered into an agreement to purchase a 57.98% stake of Beijing Jialin Pharmaceutical for an aggregate consideration of 3.68 billion renminbi ($599 million) in cash. 3 September 2014
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze